phiopharma.com (PHIO) Company Cash on Hand

Corporate company logo of Phio Pharmaceuticals Corp (PHIO)

Phio Pharmaceuticals (PHIO) is optimizing its RNA component supply chains, mitigating risks through a global network of research centers. The company is developing RNA interference methods to combat skin cancer, while strict FDA regulations dictate the pace of its clinical base expansion. The company's cash position illustrates current liquidity, with 0.01 showing the current value of the metric for financial stability analysis.

PHIO - Phio Pharmaceuticals Company Liquid Assets over the range 07/04/2022 - 11/21/2026

Analytical breakdowns for Phio Pharmaceuticals

- current price and projected stock value:
General company analysis:PHIO phiopharma.com
Brand item of Phio Pharmaceuticals

This indicator aggregates liquid assets on accounts, reflecting the fundamental stability and the ability of Phio Pharmaceuticals to sustain operational activities without external borrowing. By analyzing the cash on hand metric, an investor assesses the financing efficiency of RNA component supply chains and the diversification of Phio Pharmaceuticals research bases, where excessive growth in balances may signal stagnation in capital expenditures for therapy development.

Main competitors

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|Company Total Cash Amount MGTX|Company Cash Volume RGNX (regenxbio.com)|SLDB: Company Cash and Cash Equivalents|ocugen.com - Company Cash Volume|PACB - Company Cash Volume|BNTC: Company Cash Volume|Company Cash and Cash Equivalents DSGN|Company Cash Funds Rocket Pharmaceuticals|Company Cash on Hand 4DMT (FDMT)|Company Cash Volume LXEO|Company Liquid Assets Korro Bio Inc.|Company Cash Volume EDIT (Editas Medicine Inc)|SLN: Company Cash and Cash Equivalents|PRQR - Company Cash Funds|Company Liquid Assets codexis.com CDXS|SGMO: Company Cash Volume|Nautilus Biotechnology (NAUT) - Company Cash Volume|Company Cash Funds Metagenomi, Inc|precisionbiosciences.com (DTIL) - Company Liquid Assets|Company Cash Funds Generation Bio Co. (GBIO)|Company Liquid Assets Boundless Bio, Inc.|Company Cash Funds Exicure, Inc. XCUR|IMNN: Company Cash and Cash Equivalents|Mustang Bio Inc - Company Cash Volume|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume